[1] 李定富,王秀琪,王慧,等.BDNF基因多态性与乙型肝炎肝硬化易感性及病情进展的关联.中华医院感染学杂志,2021,31(21):3225-3229. [2] Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: Mechanistic concepts and therapeutic perspectives. Cells, 2020, 9(4):875. [3] Francoz C, Durand F, Kahn JA, et al. Hepatorenal syndrome. Clin J Am Soc Nephrol, 2019, 14(5):774-781. [4] Fida S, Khurshid SMS, Mansoor H. Frequency of hepatorenal syndrome among patients with cirrhosis and outcome after treatment. Cureus, 2020, 12(8):e10016. [5] Divens LL, Rivera SL. Hepatorenal syndrome: from the beginning to now. Crit Care Nurs Clin North Am, 2022, 34(3):321-329. [6] Xu X, Duan Z, Ding H.et al. Chinese guidelines on the management of ascites and its related complications in cirrhosis. Hepatol Int, 2019, 13(1):1-21. [7] Lyu Y, Wu H, Lau WY, et al. Impact of total splenectomy on peripheral lymphocytes and their subsets in patients with hypersplenism associated with cirrhotic portal hypertension. Sci Rep, 2021, 11(1):21246. [8] Premkumar M, Anand AC. Overview of complications in cirrhosis. J Clin Exp Hepatol, 2022, 12(4):1150-1174. [9] 中华医学会肝病学分会. 肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792. [10] Seetlani N K,Memon A R,Iftikhar F,et al. Hepatorenal syndrome in patients with cirrhosis of liver according to 2007 international ascites club criteria. J Ayub Med Coll Abbottabad,2016,28(3):578-581. [11] 罗红敏.特利加压素联合白蛋白治疗1型肝肾综合征.中华危重病急救医学,2021,33(5):556-556. [12] 王江滨.肝肾综合征的新概念.中华消化杂志,2021,41(5):312-315. [13] GinèsP, SolàE, AngeliP, et al. Hepatorenal syndrome. Nat Rev Dis Primers, 2018, 4(1): 23. [14] Habas E, Ibrahim AR, Moursi MO, et al. Update on hepatorenal syndrome: definition, pathogenesis, and management. Arab J Gastroenterol, 2022, 23(2):125-133. [15] Khemichian S, Francoz C, Nadim MK. Advances in management of hepatorenal syndrome. Curr Opin Nephrol Hypertens, 2021, 30(5):501-506. [16] Solé C, Solà E, Huelin P, et al. Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. Liver Int, 2019, 39(7):1246-1255. [17] Tranah TH, Edwards LA, Schnabl B, et al. Targeting the gut-liver-immune axis to treat cirrhosis. Gut, 2021,70(5):982-994. [18] Romanelli RG, Vitiello G, Gitto S, et al. Characterization of lymphocyte subsets in ascitic fluid and peripheral blood of decompensated cirrhotic patients with chronic hepatitis C and alcoholic liver disease: a pivotal study. Int J Immunopathol Pharmacol, 2020, 34:2058738420929587. [19] 唐建华,陈富强,孙晓军,等.乙肝患者血清lncRNA NEAT1表达与HBV-DNA载量、肝功及T淋巴细胞亚群的相关性.中国病原生物学杂志,2021,16(5):582-585,589. [20] 雷晓燕,陈星星,罗璇,等.T淋巴细胞亚群及多个细胞因子的变化与儿童乙型肝炎病毒相关性肾炎相关性分析.中华实用儿科临床杂志,2020,35(9):700-704. [21] Lee SA, Noel S, KurzhagenJT, et al. CD4+ T cell-derived NGAL modifies the outcome of ischemic acute kidney injury. J Immunol, 2020, 204(3):586-595. [22] 王小华,王伟,张妮,等.血清NGAL联合肌酐早期判断乙型肝炎肝硬化患者并发肝肾综合征的临床价值分析.实用肝脏病杂志,2018,21(5):685-688. |